{
  "meta": {
    "name": "DVO Substance Administration & Approval Metadata",
    "version": "1.0.0",
    "created_date": "2026-01-04",
    "scope": "UI-only metadata for route/frequency/setting and approval context. Not used for ranking or eligibility. Approval notes may vary by product SmPC; verify locally if needed.",
    "fields": {
      "substance_id": "string (must match therapy engine IDs)",
      "label_de": "string (from Substance Registry, for UI display)",
      "administration": {
        "route": "oral | iv | sc | mixed",
        "frequency_default": "daily | weekly | monthly | six_monthly | quarterly | yearly | mixed",
        "setting_default": "self | practice | mixed"
      },
      "approval": {
        "female": {
          "approved": "boolean",
          "population_note_de": "string"
        },
        "male": {
          "approved": "boolean",
          "population_note_de": "string"
        }
      },
      "notes_de": "short neutral UI hint"
    },
    "enums": {
      "route": [
        "oral",
        "iv",
        "sc",
        "mixed"
      ],
      "frequency_default": [
        "daily",
        "weekly",
        "monthly",
        "six_monthly",
        "quarterly",
        "yearly",
        "mixed"
      ],
      "setting_default": [
        "self",
        "practice",
        "mixed"
      ]
    }
  },
  "substances": [
    {
      "substance_id": "alendronate",
      "label_de": "Alendronat",
      "administration": {
        "route": "oral",
        "frequency_default": "weekly",
        "setting_default": "self"
      },
      "approval": {
        "female": {
          "approved": true,
          "population_note_de": "Postmenopausale Osteoporose."
        },
        "male": {
          "approved": true,
          "population_note_de": "Osteoporose beim Mann; Dosierung/Frequenz je nach Präparat (häufig tägliches Regime in älteren SmPCs, teils auch wöchentlich)."
        }
      },
      "notes_de": "Oral, nüchtern; Einnahmeregeln können die Adhärenz beeinflussen."
    },
    {
      "substance_id": "risedronate",
      "label_de": "Risedronat",
      "administration": {
        "route": "oral",
        "frequency_default": "weekly",
        "setting_default": "self"
      },
      "approval": {
        "female": {
          "approved": true,
          "population_note_de": "Postmenopausale Osteoporose."
        },
        "male": {
          "approved": true,
          "population_note_de": "Osteoporose beim Mann; zugelassen auch als 35 mg 1×/Woche (produktabhängig)."
        }
      },
      "notes_de": "Oral, Einnahmebedingungen ähnlich Bisphosphonaten; Frequenz kann je nach Präparat variieren."
    },
    {
      "substance_id": "ibandronate",
      "label_de": "Ibandronat",
      "administration": {
        "route": "mixed",
        "frequency_default": "mixed",
        "setting_default": "mixed"
      },
      "approval": {
        "female": {
          "approved": true,
          "population_note_de": "Postmenopausale Osteoporose."
        },
        "male": {
          "approved": false,
          "population_note_de": "Keine reguläre Zulassung für Osteoporose beim Mann (i.d.R. Off-Label)."
        }
      },
      "notes_de": "Oral monatlich oder i.v. quartalsweise (präparatabhängig)."
    },
    {
      "substance_id": "zoledronate",
      "label_de": "Zoledronat",
      "administration": {
        "route": "iv",
        "frequency_default": "yearly",
        "setting_default": "practice"
      },
      "approval": {
        "female": {
          "approved": true,
          "population_note_de": "Postmenopausale Osteoporose."
        },
        "male": {
          "approved": true,
          "population_note_de": "Osteoporose beim Mann."
        }
      },
      "notes_de": "i.v. meist jährlich; sehr geringe Einnahme-Last."
    },
    {
      "substance_id": "denosumab",
      "label_de": "Denosumab",
      "administration": {
        "route": "sc",
        "frequency_default": "six_monthly",
        "setting_default": "practice"
      },
      "approval": {
        "female": {
          "approved": true,
          "population_note_de": "Postmenopausale Osteoporose."
        },
        "male": {
          "approved": true,
          "population_note_de": "Osteoporose beim Mann mit erhöhtem Frakturrisiko."
        }
      },
      "notes_de": "s.c. alle 6 Monate; bei Absetzen Risiko rascher Knochenverlust (Rebound)."
    },
    {
      "substance_id": "raloxifene",
      "label_de": "Raloxifen",
      "administration": {
        "route": "oral",
        "frequency_default": "daily",
        "setting_default": "self"
      },
      "approval": {
        "female": {
          "approved": true,
          "population_note_de": "Postmenopausale Frauen."
        },
        "male": {
          "approved": false,
          "population_note_de": "Keine Zulassung für Männer."
        }
      },
      "notes_de": "Oral täglich; v.a. Wirbel-Frakturreduktion (kontextuell)."
    },
    {
      "substance_id": "bazedoxifene",
      "label_de": "Bazedoxifen",
      "administration": {
        "route": "oral",
        "frequency_default": "daily",
        "setting_default": "self"
      },
      "approval": {
        "female": {
          "approved": true,
          "population_note_de": "Postmenopausale Frauen."
        },
        "male": {
          "approved": false,
          "population_note_de": "Keine Zulassung für Männer."
        }
      },
      "notes_de": "Oral täglich (SERM)."
    },
    {
      "substance_id": "teriparatide",
      "label_de": "Teriparatid",
      "administration": {
        "route": "sc",
        "frequency_default": "daily",
        "setting_default": "self"
      },
      "approval": {
        "female": {
          "approved": true,
          "population_note_de": "Osteoporose mit hohem Frakturrisiko (indikationsabhängig)."
        },
        "male": {
          "approved": true,
          "population_note_de": "Osteoporose beim Mann (indikationsabhängig)."
        }
      },
      "notes_de": "Tägliche s.c.-Injektion; zeitlich begrenzt, anschließend Erhaltungstherapie."
    },
    {
      "substance_id": "romosozumab",
      "label_de": "Romosozumab",
      "administration": {
        "route": "sc",
        "frequency_default": "monthly",
        "setting_default": "practice"
      },
      "approval": {
        "female": {
          "approved": true,
          "population_note_de": "Postmenopausale Frauen mit schwerer Osteoporose/hohem Frakturrisiko."
        },
        "male": {
          "approved": false,
          "population_note_de": "Keine Zulassung für Männer."
        }
      },
      "notes_de": "Monatliche s.c.-Gabe (meist 12 Monate)."
    }
  ]
}